FindTrial
Sign In

Use of Levosimendan in patients with heart failure due to infection.

Levosimendan in right ventricular dysfunction due to sepsis and septic shock - NIL

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
CTRI
Registry ID
CTRI/2023/07/055023
Enrollment
45
Registered
2023-07-10
Start date
Unknown
Completion date
Unknown
Last updated
2023-07-25

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: I998- Other disorder of circulatory system

Interventions

None listed

Sponsors

Jawaharlal Nehru Medical college
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: (1) were at least 18 years of age (2) had a clinically suspected infection (3) had either septic shock (systolic BP (4)initially preserved left ventricular function(left ventricular ejection fraction >45%)

Exclusion criteria

Exclusion criteria: 1)Age 2)Pregnant women, 3)Valvular heart disease 4)Left ventricular out flow tract obstruction 5)Non sepsis related cardiac dysfunction (Ejection ï?? Confirmed or suspected acute coronary syndrome

Design outcomes

Primary

MeasureTime frame
Improvement in right ventricular functionTimepoint: within 7 days of drug administration—

Secondary

MeasureTime frame
To assess ICU mortality & morbidityTimepoint: From 8th day of drug administration to the time of discharge—

Countries

India

Contacts

Public ContactV N K SRINIVAS MUDIGANTI

Jawaharlal Nehru Medical College

anjuk.9c@gmail.com9373212986

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026